Skip to main content

Table 2 Effect of ramipril on echocardiographic measurements of left ventricular mass and function in a substudy of HOPE

From: Dose response of ACE inhibitors: implications of the SECURE trial

Echocardiographic variable Placebo Ramipril 2.5 mg/day Ramipril 10 mg/day
Δ LVMI (g/m2) 3.98 ± 25.23 4.15 ± 22.77 -2.02 ± 27.12*
Δ LVEF (%) -2.02 ± 1.54 -1.54 ± 8.94 -0.17 ± 8.62
Δ LVEDV (ml) 4.16 ± 30.89 -0.43 ± 33.3 -5.90 ± 35.17††
Δ LVESV (ml) 5.31 ± 20.49 2.90 ± 17.68 -1.90 ± 18.71††
New wall motion abnormalities 31 30 23
  1. *P < 0.05. P = 0.06. ††P < 0.01. Δ refers to study-end minus baseline measurement. HOPE =Heart Outcomes Prevention Evaluation study; LVMI = left ventricular mass index; LVEF = left ventricular ejection fraction; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume.